Register      Login
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
RESEARCH ARTICLE

High uptake of pre-exposure prophylaxis (PrEP) during early roll-out in Belgium: results from surveillance reports

Bea Vuylsteke https://orcid.org/0000-0003-0514-4372 A M , Thijs Reyniers https://orcid.org/0000-0003-3756-921X A , Catherine Lucet B , Christiana Nöstlinger A C , Jessika Deblonde D , Agnes Libois E , Anne-Sophie Sauvage F , Edwinne Deprez G , Jean-Christophe Goffard H , Sabine D. Allard I , Eric Florence https://orcid.org/0000-0002-7004-9120 J , Rémy Demeester K , Steven Callens https://orcid.org/0000-0002-7245-527X L and Marie Laga A
+ Author Affiliations
- Author Affiliations

A Unit HIV and Sexual Health, Institute of Tropical Medicine, Nationalestraat 155, 2018 Antwerp, Belgium.

B National Institute for Health and Disability Insurance, Tervurenlaan 211, 1150 Brussels, Belgium.

C Faculty of Psychology, University of Vienna, Liebiggasse 5, 1010 Vienna, Austria.

D Sciensano, Juliette Wytsmanstraat 14, 1050 Brussels, Belgium.

E University Hospital Saint-Pierre, Université Libre de Bruxelles, Rue aux Laines 105, 1000 Brussels, Belgium.

F Aids Reference Centre, University Hospital Liège, Quai Godefroid Kurth 45, 4020 Liège, Belgium.

G Sida Sol, Rue des Fontaines Roland 29, 4000 Liège, Belgium.

H Aids Reference Centre, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium.

I Aids Reference Centre, University Hospital Brussels, Laarbeeklaan 101, 1090 Brussels, Belgium.

J Aids Reference Centre, Institute of Tropical Medicine, Nationalestraat 155, 2018 Antwerp, Belgium.

K Aids Reference Centre, University Hospital Charleroi, Chaussée de Bruxelles 140, 6042 Lodelinsart, Belgium.

L Aids Reference Centre, University Hospital Ghent, Corneel Heymanslaan 10, 9000 Ghent, Belgium.

M Corresponding author. Email: bvuylsteke@itg.be

Sexual Health 16(1) 80-83 https://doi.org/10.1071/SH18071
Submitted: 6 April 2018  Accepted: 23 August 2018   Published: 30 November 2018

Abstract

Background: Since 1 June 2017, oral pre-exposure prophylaxis (PrEP) could be prescribed and reimbursed in Belgium as prophylactic medication for people who are at increased risk of HIV acquisition. The aim of this study was to determine the uptake of daily and event-driven PrEP in Belgium during the first 9 months of roll-out. Methods: Routine aggregated data on the number of reimbursement requests and the number of boxes of Truvada (Gilead Sciences, Cambridge, UK) delivered for PrEP through the Belgian pharmacies were obtained from the National Institute for Health and Disability Insurance. We also collected aggregated data from seven Aids Reference Centres (ARCs) currently providing most of the PrEP care in Belgium. Results: From 1 June 2017 to 28 February 2018, 1352 requests for reimbursement were approved by the National Institute for Health and Disability Insurance. Almost 98% of those who bought at least one box of 30 tablets of emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) in a Belgian pharmacy were male, and most (67%) were between 30 and 50 years of age. According to data obtained from ARCs, the proportion of those choosing event-driven PrEP initially ranged between 29% and 73%. Conclusions: The uptake of PrEP in Belgium since the start of the roll-out in June 2017 has been high, and almost entirely limited to men who have sex with men, of whom 43% initially prefer a non-daily regimen. A better understanding is needed as to why other populations, such as sub-Saharan African migrants, are not accessing PrEP, as well as the development of a more sustainable PrEP delivery model.

Additional keywords: HIV prevention, implementation.


References

[1]  European Centre for Disease Prevention and Control (ECDC)/World Health Organization (WHO) Regional Office for Europe. HIV/AIDS surveillance in Europe 2017–2016 data. Stockholm: ECDC; 2017.

[2]  Sasse A, Deblonde J, Van Beckhoven D. Epidemiologie van AIDS en HIV infectie in België (toestand op 31 december 2016). 2017. Available online at: https://epidemio.wiv-isp.be/ID/reports/Epidemiologie%20van%20AIDS%20en%20HIV-infecties%20in%20Belgie.%20Jaarrapport%202016l.pdf [verified 5 September 2018]

[3]  Verhofstede C, Dauwe K, Fransen K, Van Laethem K, Van den Wijngaert S, Ruelle J, Delforge M-L, Vancutsem E, Vaira D, Stoffels K, Ribas SG, Dessilly G, Debaisieux L, Pierard D, Van Ranst M, Hayette M-P, Deblonde J, Sasse A, Van Beckhoven D, Mortier V. Phylogenetic analysis of the Belgian HIV-1 epidemic reveals that local transmission is almost exclusively driven by men having sex with men despite presence of large African migrant communities. Infect Genet Evol 2018; 61 36–44.
Phylogenetic analysis of the Belgian HIV-1 epidemic reveals that local transmission is almost exclusively driven by men having sex with men despite presence of large African migrant communities.Crossref | GoogleScholarGoogle Scholar |

[4]  McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, Mackie N, Bowman C, Lacey CJ, Apea V, Brady M, Fox J, Taylor S, Antonucci S, Khoo SH, Rooney J, et al Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016; 387 53–60.
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.Crossref | GoogleScholarGoogle Scholar |

[5]  Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, et al On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015; 373 2237–46.
On-demand preexposure prophylaxis in men at high risk for HIV-1 infection.Crossref | GoogleScholarGoogle Scholar |

[6]  BREACH Belgian Research on AIDS and HIV Consortium. HIV plan 2014–2019 Belgium. 2013. Available online at: http://www.breach-hiv.be/media/docs/HIVPLan/NationalPlanEng.pdf [verified 5 September 2018]

[7]  De Baetselier I, Reyniers T, Nöstlinger C, Wouters K, Fransen K, Crucitti T, Kenyon C, Buyze J, Schurmans C, Laga M, Vuylsteke B, Be-PrEP-Ared Study Group. Pre-exposure prophylaxis (PrEP) as an additional tool for HIV prevention among men who have sex with men in Belgium: the Be-PrEP-ared study protocol. JMIR Res Protoc 2017; 6 e11
Pre-exposure prophylaxis (PrEP) as an additional tool for HIV prevention among men who have sex with men in Belgium: the Be-PrEP-ared study protocol.Crossref | GoogleScholarGoogle Scholar |

[8]  Molina J, Pialoux G, Ohayon M, Cotte L, Valin N, Ghosn J. One-year experience with pre-exposure prophylaxis (PrEP) implementation in France with TDF/FTC. Proceedings of the International AIDS Conference; 23–26 July 2017; Paris. Geneva: International AIDS Society; 2017. p. 481 [Abstract WEPEC0939]

[9]  Reyniers T, Nöstlinger C, Laga M, De Baetselier I, Crucitti T, Wouters K, Smekens B, Buyze J, Vuylsteke B. Choosing between daily and event-driven Pre-Exposure Prophylaxis: results of a Belgian PrEP demonstration project. J Acquir Immune Defic Syndr 2018; 79 186–94.
Choosing between daily and event-driven Pre-Exposure Prophylaxis: results of a Belgian PrEP demonstration project.Crossref | GoogleScholarGoogle Scholar |

[10]  Molina J-M. PrEP rollout in France. Proceedings of the 21st International AIDS Conference; 18–22 July 2016; Durban. Durban: AIDS2016; 2016. [Abstract WEWSO804]

[11]  Loos J, Nöstlinger C, Reyniers T, Colebunders R, Jespers V, Manirankunda L, Berghe WV, Vuylsteke B, Laga M. PrEP for African migrants in Europe? A research agenda. Lancet HIV 2016; 3 e505–7.

[12]  Reyniers T, Vuylsteke B, Pirotte B, Hoornenborg E, Bil J, Wouters K, et al Physicians’ preparedness for PrEP – results of an online survey in Belgium. Sex Health 2018;
Physicians’ preparedness for PrEP – results of an online survey in Belgium.Crossref | GoogleScholarGoogle Scholar |

[13]  Vuylsteke B. Update on PrEP. BREACH Symposium, Anderlecht. 2017. Available online at: http://www.breach-hiv.be/media/docs/BREACHSympo2017/04VuylstekeUpdateonPrEP-final.pdf [verified 5 September 2018]

[14]  Apers L, Platteau T, Caluwaerts S. PrEP from a clinician’s perspective. Acta Clin Belg 2018; 73 165–6.
PrEP from a clinician’s perspective.Crossref | GoogleScholarGoogle Scholar |

[15]  Traeger MW, Schroeder SE, Wright EJ, Hellard ME, Cornelisse VJ, Doyle JS, Hellard ME, Cornelisse VJ, Doyle JS, Stoové MA. Effects of pre-exposure prophylaxis for the prevention of HIV infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis. Clin Infect Dis 2018; 67 676–86.
Effects of pre-exposure prophylaxis for the prevention of HIV infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar |